 |
CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid |
|---|---|
| Trade Name | |
| Orphan Indication | Graft Versus Host Disease |
| USA Market Approval | USA |
| USA Designation Date | 2016-02-18 00:00:00 |
| Sponsor | Bellicum Pharmaceuticals, Inc.;2130 West Holcombe Boulevard;Houston, Texas, 77030 |
